================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 9, 2004 (June 7, 2004)
Pharmion Corporation
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-50447 84-1521333
- ---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
2525 28th Street, Boulder, Colorado 80301
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 720-564-9100
------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure
On June 7, 2004, Pharmion Corporation issued a press release
entitled "Pharmion Corporation Files Registration Statement for
Follow-On Offering," announcing that it has filed a registration
statement relating to a proposed underwritten public offering of
4,000,000 shares of its common stock. In addition, Pharmion
announced plans to grant an option to the underwriters to purchase
up to an additional 600,000 shares of its common stock to cover
over-allotments, if any. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information And Exhibits
(c) Exhibits
99.1 Press Release, dated June 7, 2004, entitled "Pharmion
Corporation Files Registration Statement for Follow-On Offering."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMION CORPORATION
Date: June 9, 2004 By: /s/ Erle T. Mast
--------------------------
Erle T. Mast
Chief Financial Officer
2